#Scinai Immunotherapeutics #Israel #Jerusalem #CDMO Services #NanoAbs

Scinai Immunotherapeutics to Connect with Investors and Showcase Innovations at BIO-Europe Spring 2025

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a pioneering biopharmaceutical company, is gearing up for an important appearance at the BIO-Europe Spring 2025 conference, scheduled for March 17-19 in Milan, Italy. This event presents a significant opportunity for Scinai to engage with key stakeholders and highlight its cutting-edge pipeline in inflammation and immunology (I&I), alongside its boutique contract development and manufacturing organization (CDMO) services.

Engaging Investors and Partners

The conference will feature Scinai's CEO, Amir Reichman, as well as CTO, Dr. Dalit Weinstein-Fischer, and Business Development Director, Solomon Gahtan. The leadership team is set to hold strategic meetings with:

• - Potential pharmaceutical partners interested in collaborating on Scinai's innovative NanoAbs (nano-sized VHH antibodies) that target a range of diseases with pressing medical needs.
• - Prospective clients seeking end-to-end biologics CDMO services from Scinai.
• - Institutional and private investors intrigued by Scinai's unique value proposition in the biopharmaceutical sector.

Attendees are invited to arrange meetings through the official conference partnering platform or directly via email at [email protected] Throughout the event, Scinai's team will also be accessible at booth #22, displaying its comprehensive CDMO services and capabilities.

Innovative CDMO Capabilities

Scinai's CDMO services, introduced through its subsidiary Scinai Bioservices, offer a robust framework for drug development, operating out of a state-of-the-art facility in Jerusalem. This facility complies with cGMP (current Good Manufacturing Practices) and is set up to meet stringent European Medicines Agency and FDA regulations. Encompassing approximately 20,000 square feet, Scinai's manufacturing site includes extensive clean rooms and laboratories that enable the seamless execution of various drug development projects.

Since launching its CDMO division in 2024, Scinai has successfully partnered with multiple biotech firms, facilitating upstream and downstream process development, analytical method advancement, and drug manufacturing for both preclinical and clinical applications. Scinai has gas also established a partnership with Ayana Pharma for liposomal encapsulated drug development services, further solidifying its position in the biopharmaceutical landscape.

Supporting Early-Stage Biotech

Scinai's U.S. subsidiary, Scinai Bioservices Inc., actively supports early-stage biotech companies based in the United States by addressing the escalating demand for CDMO services. This initiative allows these companies, particularly those bolstered by federal grant funding, to utilize their grant resources without hindrance from regulations like the BIOSECURE Act. Through this strategy, Scinai aims to enhance the viability of drug development endeavors by easing the financial burdens often encountered by startups.

The Future of Scinai Immunotherapeutics

Scinai Immunotherapeutics stands at the forefront of biopharmaceutical innovation, focusing not only on advancing its internal pipeline of I&I biotherapeutics but also on providing tailored developmental services that empower other biotech companies. The upcoming BIO-Europe Spring conference marks a pivotal moment for Scinai, as it seeks to forge new alliances that will bolster its market position and drive its mission to address significant medical needs through innovative solutions. For more information about Scinai Immunotherapeutics and its initiatives, explore their website at www.scinai.com.